NCT02575404 2023-06-05GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsProvidence Health & ServicesPhase 1 Completed36 enrolled